BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-16@catalystbrief.girapphe.com
DTSTAMP:20261117T061842Z
LAST-MODIFIED:20261117T061842Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Novartis Pharmaceuticals — Ianalumab [Apr 2027]
DESCRIPTION:Phase 3 primary completion: Phase 3 Study to Evaluate Two Regim
 ens of Ianalumab on Top of Standard-of-care Therapy in Patients With Syste
 mic Lupus Erythematosus (SIRIUS-SLE 1).\nSource: https://clinicaltrials.go
 v/study/NCT05624749\nhttps://catalystbrief.girapphe.com/e/16?lang=en\nNot 
 investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/16?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
